지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
초록· 키워드
오류제보하기
Objective : There is no proven regimen to reduce the severity of stroke in patients with acute cerebral infarction presenting beyond the thrombolytic time window. Ozagrel sodium, a selective thromboxane A2 synthetase inhibitor, has been known to suppress the development of infarction. The antiplatelet effect is improved when aspirin is used together with a thromboxane synthetase inhibitor. Methods : Patients with non-cardiogenic acute ischemic stroke who were not eligible for thrombolysis were randomly assigned to two groups; one group received ozagrel sodium plus 100 mg of aspirin (group 1, n=43) and the other 100 mg of aspirin alone (group 2, n=43). Demographic data, cardiovascular risk factors, initial stroke severity [National Institute of Health Stroke Scale (NIHSS) and motor strength scale] and stroke subtypes were analyzed in each group. Clinical outcomes were analyzed by NIHSS and motor strength scale at 14 days after the onset of stroke. Results : There were no significant differences in the mean age, gender proportion, the prevalence of cardiovascular risk factors, stroke subtypes, and baseline neurological severity between the two groups. However, the clinical outcome for group 1 was much better at 14 days after the onset of stroke compared to group 2 (NIHSS score, p=0.007, Motor strength scale score, p<0.001). There was one case of hemorrhagic transformation in group 1, but there was no statistically significant difference in bleeding tendency between two groups. Conclusion : In this preliminary study, thromboxane A2 synthetase inhibitor plus a low dose of aspirin seems to be safe and has a favorable outcome compared to aspirin alone in patients with acute ischemic stroke who presented beyond the thrombolytic time window.
목차
등록된 정보가 없습니다.
참고문헌 (28)
참고문헌 신청
Adams HP Jr / 1993 / Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment / Stroke 24:35~41
Albers GW / 2008 / Antithrombotic and thrombolytic therapy for ischemic stroke : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) / Chest 133:630~669
Bertelé V / 1983 / Platelet thromboxane synthetase inhibitors with low doses of aspirin : possible resolution of the “aspirin dilemma” / Science 220:517~519
Brandt T / 1996 / Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome / Stroke 27:875~881
Brott T / 2000 / Treatment of acute ischemic stroke / N Engl J Med 343:710~722
Albers GW / 2008 / Antithrombotic and thrombolytic therapy for ischemic stroke : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) / Chest 133:630~669
Bertelé V / 1983 / Platelet thromboxane synthetase inhibitors with low doses of aspirin : possible resolution of the “aspirin dilemma” / Science 220:517~519
Brandt T / 1996 / Thrombolytic therapy of acute basilar artery occlusion. Variables affecting recanalization and outcome / Stroke 27:875~881
Brott T / 2000 / Treatment of acute ischemic stroke / N Engl J Med 343:710~722
이 논문의 저자 정보
최근 본 자료
댓글(0)
0